Finch Therapeutics Group Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“We have used our Human-First Discovery platform to develop FIN-211, an Enriched Consortia product candidate that we are advancing for the treatment of the gastrointestinal and behavioral symptoms of ASD. Scientific research in human and animal models have highlighted the “gut-brain axis” linking dysbiosis to neurological and neurobehavioral conditions, as the microbiome impacts the enteric nervous system and the production of neurotransmitters.” (Page 3) Read the full document
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company. The Company leveraging Human-First Discovery platform to develop a class of orally administered biological drugs. It is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it.
Company Website: https://www.finchtherapeutics.com